The lawsuit alleges Abode Services violated the California Labor Code by failing to pay its employees for all time worked.

SAN FRANCISCO, Sept. 28, 2026 /PRNewswire/ -- The San Francisco labor law attorneys at Zakay Law Group, APLC, filed a class action complaint against Abode Services, Abode Housing Development dba Allied Housing, Inc., and Abode Property Management (collectively, "Abode Services") for allegedly failing to provide meal and rest breaks. The class action lawsuit, Case No. 26CV211113, is currently pending in the Alameda County Superior Court of the State of California. A copy of the Complaint can be read here.

According to the lawsuit, Abode Services allegedly violated California Labor Code Sections §§ 201, 202, 203, 204, 210, 226.7, 510, 512, 558, 1194, 1197, 1197.1, 1198, 1198.5 and 2802 by failing to: (1) pay minimum wages; (2) pay overtime wages; (3) provide required meal and rest periods; (4) provide accurate itemized wage statements; (5) provide wages when due; (6) reimburse for required business expenses; and (7) permit inspection of employee records.

As a result of their rigorous work schedules, Abode Services' employees were allegedly unable to take off duty rest breaks and were not fully relieved of duty for rest periods. Specifically, the lawsuit alleges employees were required from time-to-time to work in excess of four (4) hours without being provided ten (10) minute rest periods as a result of their overburdened work requirements and inadequate staffing. Further, the lawsuit alleges these employees were denied their first rest periods of at least ten (10) minutes for some shifts worked of at least two (2) to four (4) hours from time to time, a first and second rest period of at least ten (10) minutes for some shifts worked of between six (6) and eight (8) hours from time to time, and a first, second and third rest period of at least ten (10) minutes for some shifts worked of ten (10) hours or more from time to time. Additionally, Abode Services' employees were also allegedly not provided with one-hour wages in lieu thereof. As a result of their allegedly rigorous work schedules and inadequate staffing, Abode Services' employees were from time to time allegedly denied their proper rest periods by Abode Services.

If you would like to know more about the Abode Services lawsuit, please contact Attorney Jackland Hom today by calling (619) 255-9047.

Zakay Law Group, APLC is a labor and employment law firm located in San Diego, California that serves employees across California and dedicates its practice to fighting for employees who have been wronged by their employers due to unfair employment practices. Contact one of their attorneys today if you need help with workplace issues regarding wage and hour, wrongful termination, retaliation, discrimination, and harassment.

-THIS IS AN ATTORNEY ADVERTISEMENT (Rules Prof. Conduct, rule 7.2)-

SOURCE Zakay Law Group, APC

Share this article

Syracuse practice, part of U.S. Urology Partners, a General Atlantic company, will run a first proof of concept of FuseRx, with ACRO clinical pathways built in, at its radiation oncology program in Syracuse

SYRACUSE, N.Y. and BOONE, N.C., Sept. 28, 2026 /PRNewswire/ -- Fuse Oncology and Associated Medical Professionals of NY (AMP), an affiliate of U.S. Urology Partners, a General Atlantic company, today announced a strategic collaboration under which AMP will run a proof of concept of FuseRx, the clinical workflow platform for radiation oncology, at its Center of Advanced Radiation Excellence in Syracuse.

Urology and radiation oncology meet at prostate cancer. It is the most common cancer in American men after skin cancer — the American Cancer Society expects about 333,800 new cases in 2026 — and it is diagnosed, in almost every case, by a urologist. Roughly a third of men with localized disease go on to radiation as their primary treatment. Many large independent urology groups, AMP among them, have brought radiation oncology in-house so that a patient is diagnosed, counseled and treated by one team. The workflow behind that care, though, still runs across separate systems.

FuseRx is built to take a patient from consult to treatment with the physician, physicist, dosimetrist, therapist and nurse working from one plan. The proof of concept at AMP starts with the physician's consult workflow — the consult note and treatment intent, with the applicable ACRO pathway at the point of decision — and will extend to the other roles as the full workflow rolls out over the coming months. FuseRx works with the EMR and oncology information system a practice already has. Fuse and ACRO announced their agreement to integrate ACRO's clinical pathways into Fuse's software in March 2025.

The proof of concept is led by Steven E. Finkelstein, MD, DABR, FACRO, FASTRO, National Director of the Center of Advanced Radiation Excellence and Director of Radiation Oncology Research for AMP and U.S. Urology Partners. Dr. Finkelstein was named a Fellow of the American Society for Radiation Oncology in July 2026, serves on ACRO's Board of Chancellors and chairs the board of ACRO's Luther Brady Foundation. In August, his team at AMP treated the first patient in the United States under Pluvicto's newly approved indication for metastatic hormone-sensitive prostate cancer.

"A urology practice sees prostate cancer from the first PSA to the last follow-up. When radiation is the right answer, the patient shouldn't wait while paperwork moves between systems," said Dr. Finkelstein. "We want to see whether one workflow, with ACRO's pathways built in, gets our patients from consult to treatment faster and more consistently. Syracuse is where we find out."

"Independent urology is where a lot of prostate cancer radiation happens, and it's a setting built for speed — one team, one roof. That's a good place to test an end-to-end workflow for radiation oncology," said James Bauler, CEO of Fuse Oncology. "Dr. Finkelstein and AMP are the right partners to do it with."

About Fuse Oncology

Fuse Oncology is a healthcare technology company focused on radiation oncology, delivering the operational layer for the clinical and administrative workflow. Fuse delivers SaaS solutions that break down healthcare workflow and data silos to create a seamless experience for clinicians. By placing the broader electronic medical record system at the center of the architecture, Fuse eliminates duplicative and inefficient efforts to enable a future where oncology care moves at the speed of patients. For more information, visit FuseOnc.com. Stay updated on our latest developments by following us on LinkedIn @fuseoncology.

SOURCE Fuse Oncology, Inc.

Share this article

Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder

Appointments of Professor Lawrence Loh, Associate Professor Eugene K.B. Tan, Professor Louis Chen and Farah Jaafar deepen RFI's expertise in law, governance, digital policy and cross-border capital markets

SINGAPORE, Sept. 28, 2026 /PRNewswire/ -- The Responsible Fintech Institute (RFI) has appointed Professor Lawrence Loh, Associate Professor Eugene K.B. Tan, Professor Louis Chen and Ms Farah Jaafar as Executive Fellows. RFI has also elevated Distinguished Professor Patrick H. M. Loh, who joined as an Executive Fellow in April 2026, to Co-Founder, in recognition of his contributions to the Institute's strategic direction.

The appointments come as digital finance goes mainstream and regulators, institutions and technology providers seek to ground innovation in digital assets, AI and cross-border payments in sound legal, ethical and governance foundations.

As Executive Fellows, they will engage regulators and standard-setting bodies, contribute to principles-based industry frameworks, and strengthen RFI's partnerships across the region.

Welcoming the appointments, Chia Hock Lai, Chairman of RFI, said, "Lawrence, Eugene, Louis and Farah bring deep experience in law, governance, digital policy and capital market development, the disciplines that responsible digital finance depends on. I also congratulate Patrick on becoming a Co-Founder, recognising his central role in building the Institute."

Professor Lawrence Loh is Director of the Centre for Governance and Sustainability at NUS Business School, where he leads the Singapore Governance and Transparency Index and the ASEAN Corporate Governance Scorecard project. He holds a PhD in Management from the Massachusetts Institute of Technology and is a regular commentator on governance and sustainability for outlets including the BBC, Bloomberg, CNN and The Straits Times.

"Trust is the foundation of every financial system, and it is built on transparency and good governance," said Professor Lawrence Loh. "I am pleased to help RFI support an industry that grows responsibly and sustainably."

Associate Professor Eugene K.B. Tan is Associate Professor of Law at Singapore Management University (SMU) and an advocate and solicitor of the Supreme Court of Singapore. Educated at the National University of Singapore, the London School of Economics and Stanford University, where he was a Fulbright Fellow, he specialises in constitutional and administrative law and the ethics and policy of artificial intelligence. He served as a Nominated Member of Parliament from 2012 to 2014 and, from 2019 to 2026, as Singapore's Representative and Alternate Representative to the ASEAN Intergovernmental Commission on Human Rights.

"As AI and digital assets reshape financial services, the key questions are about accountability and public trust, not just technology," said Associate Professor Tan. "I look forward to helping RFI develop frameworks that are principled, practical and grounded in the rule of law."

Professor Louis Chen is widely recognised for his contributions to digital governance, sustainable digital economy development and cross-sector institutional collaboration. Through his leadership at the Digital Governance Association (DGA), he has helped advance dialogue on responsible innovation, AI governance and the future of digital ecosystems.

"Trusted digital finance depends on governance that keeps pace with technology," said Professor Chen. "I look forward to helping RFI bring policymakers, academics and industry together towards a secure, interoperable digital economy."

Ms Farah Jaafar is a senior executive, board advisor and governance leader with close to 30 years of experience across capital markets, offshore finance, fintech and digital assets. As former Chief Executive Officer of Labuan IBFC Inc., she led the international positioning of Malaysia's international business and financial centre as a regional hub for cross-border financial solutions. She has chaired risk committees in regulated brokerages and pioneered licensed fintech and digital asset infrastructure in Asia. She chairs the Women in Fintech Group of the Asia Fintech Alliance, which represents fintech associations across 15 Asian markets.

"A rising tide lifts all boats," said Ms Jaafar. "Digital finance can widen access and create opportunity, but only if it earns the confidence of regulators, investors and the public. I look forward to strengthening that collaboration with RFI."

Distinguished Professor Patrick H. M. Loh was conferred the inaugural Singapore Distinguished Professor title by Murdoch University, Australia, in 2024. He is Senior Fellow and Advisory Board Member at the Centre for Governance and Sustainability at NUS Business School, and Chairman of the Advisory Board at Murdoch University in Singapore. He was awarded the Public Service Star (BBM) and the Public Service Medal (PBM) by the President of the Republic of Singapore.

"The calibre of leaders joining us shows that responsible innovation needs collaboration across law, governance, industry and policy," said Distinguished Professor Patrick Loh. "I look forward to expanding RFI's impact across the region and beyond."

The RFI Executive Fellowship is designed for senior leaders with at least 20 years of experience in executive leadership and a demonstrated track record in shaping financial policy or institutional strategy. Fellows are expected to operate with institutional neutrality while contributing to globally aligned and responsible financial systems.

About the Responsible Fintech Institute (RFI)

The Responsible Fintech Institute (RFI) is a global nonprofit organisation based in Singapore. Its goal is to create a safe, trustworthy and reliable future for digital finance by building the digital utilities that support responsible innovation. RFI brings together public and private sector stakeholders to help build the rules and technology needed for new digital financial tools, and to make the digital asset sector sustainable and inclusive. Learn more at responsiblefintech.org.

SOURCE Responsible Fintech Institute (RFI)

Share this article

NEW YORK, Sept. 28, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"), of the important October 13, 2026 lead plaintiff deadline.

So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

NEW YORK, Sept. 28, 2026 /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Taboola.com Ltd. (NASDAQ: TBLA) between May 6, 2026 and August 4, 2026, both dates inclusive (the "Class Period"), of the important October 20, 2026 lead plaintiff deadline.

So what: If you purchased Taboola.com securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Taboola.com class action, go to https://rosenlegal.com/cases/taboolacom-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Taboola.com was seeing an increase in low-quality publishers; (2) as a result, Taboola.com would need to take an aggressive approach to exiting these low-quality publisher relationships, impacting earnings; (3) as a result, the value of Taboola.com's publisher relationships was overstated; and (4) as a result of the foregoing, defendants' positive statements about Taboola.com's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Taboola.com class action, go to https://rosenlegal.com/cases/taboolacom-ltd/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Fluence Energy, Inc. (NASDAQ: FLNC) resulting from allegations that Fluence Energy may have issued materially misleading business information to the investing public.

So what: If you purchased Fluence Energy securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/fluence-energy-inc-2026-09/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 16, 2026, Fluence Energy issued a press release entitled "Fluence Energy Announces Revised Guidance for Fiscal Year 2026; Management to Host Conference Call at 5 PM Eastern Time Today." The press release stated that Fluence Energy was revising its 2026 guidance to provide for "[r]evenue of approximately $2.4 billion compared to the prior guidance midpoint of approximately $3.0 billion." Further, the press release announced that it was adjusting its guidance to reflect an adjusted EBITDA loss of "approximately $200.0 million compared to prior guidance midpoint of a loss of approximately $10.0 million."

On this news, Fluence Energy stock fell over 20%, to open at $7.23 on September 17, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.

     Phillip Kim, Esq.

     The Rosen Law Firm, P.A.

     275 Madison Avenue, 40th Floor

     New York, NY 10016

     Tel: (212) 686-1060

     Toll Free: (866) 767-3653

     Fax: (212) 202-3827

     [email protected]

     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Share this article

Statement from Kathy Crosby, CEO and President of Truth Initiative

WASHINGTON, Sept. 28, 2026 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced that it plans to evaluate changes to the framework for applications for new tobacco products like e-cigarettes and nicotine pouches to make it easier for them to be sold. While the agency has not fully outlined what changes it may propose, any action that weakens the scientific evidence required or diminishes the review process would undermine the FDA's regulatory role in protecting public health.

The law requires the FDA to evaluate a number of key pieces of information about a proposed new product, including its components, ingredients, toxicological profile and health impact. It also must consider the risks and benefits to the population as a whole, including users and non-users of tobacco products, particularly youth.

The agency's review of these products against a rigorous public health standard is critical in balancing two important objectives: providing adults who smoke with access to products that have demonstrated they pose less risk if used exclusively, while preventing initiation among youth and those who don't already use tobacco or nicotine products.

With more than 24 million U.S. adults who still smoke, there's a clear need to provide an off-ramp from combustible cigarettes – the leading cause of preventable disease and death. Total cessation is always the goal, but access to FDA-authorized alternatives may play an important role for those unwilling or unable to quit nicotine. Adults who use these products deserve confidence that they have been thoroughly evaluated and are not exposing them to unnecessary or unforeseen health risks.

At the same time, we cannot allow new products to become an on-ramp for addiction among young people and nicotine-naïve individuals. This is critical to ensuring authorized products remain appropriate for the protection of public health, especially as the agency considers a wider variety of flavors and higher nicotine strengths.

Achieving these objectives is made significantly more difficult by today's largely uncontrolled marketplace. While the potential FDA changes are intended to smooth the process for companies meaningfully participating in the regulatory system, the biggest obstacle is the continued proliferation of products sold by companies that have no intention of complying with the law.

Nearly 7,500 illegal e-cigarette and nicotine pouch products have flooded the market, exploiting enforcement gaps to continue marketing highly addictive and appealing products with largely untested ingredients that put all consumers at risk.

The goal shouldn't be how quickly products can move through the review process. It should be to ensure the FDA has the scientific information necessary to determine whether products meet the public health standard and that products authorized through that process are the only ones available in the marketplace.

About Truth Initiative

Truth Initiative® is a national nonprofit public health organization committed to a future free from lifelong addiction, fostering healthier lives and a more resilient nation. Our mission is to prevent youth and young adult nicotine addiction and empower quitting for all. Through our evidence-based, market-leading cessation intervention, EX® Program, and national public education campaigns, we lead the fight against youth and young adult tobacco use. Learn more at truthinitiative.org.

SOURCE Truth Initiative

Share this article

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis

- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment.

- Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing.

- Placebo-adjusted reduction in PASI score reached 65.9% in mild-to-moderate plaque psoriasis patients 15 days after last dose (28th dose), which supports potential once-weekly oral dosing.

- Strong target engagement after 28-day dosing, indicated by elevated plasma interleukin-17A (IL-17A) levels.

- Once-daily 200 mg 28-day treatment was safe and well tolerated with only mild adverse events observed. No alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations were observed. No hepatic safety signal was detected.

HONG KONG, Sept. 28, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in the U.S. The objectives of the Phase I study were to evaluate the safety, efficacy and pharmacokinetics of once-daily 200 mg of ASC50 after 28-day treatment in mild-to-moderate plaque psoriasis patients (NCT07024602).

Key Findings

- Achieved a placebo-adjusted reduction of 48.9% in psoriasis area and severity index (PASI) score in mild-to-moderate plaque psoriasis patients after once-daily 200 mg 28-day treatment.

- Steady-state elimination half-life after 28-day treatment in patients was 6.5 days, supporting potential once-weekly oral dosing.

- The placebo-adjusted reduction in PASI score increased to 60.7% and 65.9% 6 days and 15 days, respectively, after the last dose (28th dose). These data support potential once-weekly oral dosing.

- 200 mg once-daily dosing demonstrated comparable reduction in PASI score to published secukinumab data (not head-to-head study). Secukinumab is the marketed interleukin-17A (IL-17A) antibody drug.

- Strong target engagement after 28-day dosing, indicated by elevated plasma IL-17A levels.

- Once-daily 200 mg 28-day treatment was safe and well tolerated. All adverse events (AEs) were mild (Grade 1) and transient. No serious adverse events (SAEs) were reported. There was no discontinuation in the study. No alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations were observed. No hepatic safety signal was detected.

"Strong efficacy and encouraging safety and pharmacokinetic data from this proof-of-concept clinical trial support ASC50's potential to be a first-in-class and best-in-class oral small molecule IL-17A inhibitor, offering patients a needle-free administration option to injectable antibody therapies. ASC50's novel scaffold exhibited a steady-state elimination half-life of 6.5 days in patients, supporting the potential for once-weekly oral dosing," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "ASC50 has the potential to be a differentiated oral alternative compared to injectable antibody therapies and will benefit patients with once-weekly oral dosing."

ASC50 is an in-house discovered and developed oral small molecule inhibitor targeting IL-17A, an important biologically and commercially validated target for multiple autoimmune and inflammatory diseases, including psoriasis. ASC50 is a new chemical entity (NCE) with a novel scaffold.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected] 

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected] 

SOURCE Ascletis Pharma Inc.

Share this article

UMG is advancing its data integration center and becomes the first German university hospital to introduce MDClone's internationally established ADAMS model.

Göttingen, Germany and BEER-SHEVA, Israel, Sept. 28, 2026 /PRNewswire/ -- The University Medical Center Göttingen (UMG) is the first hospital in Germany and the European Union to introduce MDClone's ADAMS platform. The platform will build on UMG's existing data integration center, UMG-MeDIC, making the clinical data already consolidated there easier and more secure to use for research, patient care, and quality management.

In doing so, UMG adopts ADAMS by MDClone, a data utilization model already in use at leading international healthcare institutions such as UChicago Medicine, Manchester University NHS Foundation Trust, and Sheba Medical Center.

"With ADAMS, we are the first university medical center in Germany and the EU to adopt an internationally proven model of data utilization. Our aim is to make our data infrastructure even more accessible to our staff," says Prof. Dr. Wolfgang Brück, Chairman of the Executive Board, Executive Board Member for Research and Teaching, and Dean of the Faculty of Medicine at the University Medical Center Göttingen. "Particularly in an increasingly challenging economic environment, innovation is becoming a decisive factor for the future viability of hospitals. Data can help us better understand care processes, identify areas for improvement, and advance medical quality and economic efficiency together on a data-driven basis."

With ADAMS, authorized staff will be able to explore longitudinal clinical data independently within a controlled and secure framework and investigate questions without relying on central IT or analytics resources for every analysis. The goal is to make data available more quickly for research questions, the further development of treatment pathways, quality improvement, and the analysis of clinical processes.

Synthetic Data for Faster Research Projects and Stronger Data Protection

Another focus is on synthetic data. Based on real clinical data, the ADAMS platform can generate synthetic datasets that reflect the statistical properties of the original data without sharing real patient records. This opens up additional opportunities for research, for the development and testing of AI applications, and for collaboration with other scientific institutions and external partners.

"With the Medical Informatics Initiative, Germany has created a strong foundation for the use of clinical data. The task now is to generate as much value as possible from this infrastructure for research and patient care," says Bruno Lempernesse, CEO of MDClone. "Internationally, we see healthcare systems moving from merely providing data toward active, organization-wide data utilization. The University Medical Center Göttingen is now the first institution in Germany and the EU to take this path."

UMG-MeDIC was established as part of the nationwide Medical Informatics Initiative (MII). With ADAMS, UMG is systematically advancing this existing infrastructure and adding a utilization layer for research, patient care, and quality management. This is intended to ensure that the investments made have a lasting impact beyond individual funding periods.

About the University Medical Center Göttingen

The University Medical Center Göttingen (UMG) unites the Faculty of Medicine of the Georg-August-University and the University Hospital under one roof in an integrated model. Alongside research, teaching, and transfer, patient care is one of UMG's core responsibilities.

As the only tertiary care provider in southern Lower Saxony, the hospital has approximately 1,700 inpatient and day-patient beds. All basic medical disciplines are represented, as well as a wide range of specialized disciplines in diagnostics and therapy. Each year, UMG treats around 55,000 inpatients and approximately 280,000 outpatients.

With nearly 9,800 employees, UMG and its subsidiaries are among the largest employers in the region. Around 60 clinics, institutes, and departments stand for high-quality patient care, excellent research, modern teaching, and innovative technology transfer.

About MDClone

MDClone helps healthcare organizations turn their data into continuous and measurable improvement. Through the ADAMS Platform and ADAMS Center operating model, clinicians, researchers, and operational leaders gain governed self-service access to data to identify opportunities, take action, measure results, and scale what works. Built specifically for healthcare, MDClone combines longitudinal real-world data, privacy-preserving synthetic data, and AI capabilities to drive measurable clinical, operational, research, and financial outcomes. MDClone works with leading healthcare organizations and academic institutions in North & South America, Europe, and Israel.

SOURCE MDClone

Share this article

askVERA's Easy Read software is available in consumer (B2C) and business (B2B) versions, both with built-in Plain English.

LONDON, Sept. 28, 2026 /PRNewswire/ -- askelie®, the UK-based AI platform company behind the ELIE (Ever Learning Intelligent Engine) platform, today announced the launch of askVERA, a new AI-powered service that helps people and organisations understand complex documents and communications.

askVERA is available in two versions: a consumer offering for individuals who need to understand contracts, letters, policies or official correspondence, and a business version for organisations that want to make their own documents and communications more accessible to customers, staff and the public. Both versions include askVERA's Plain English and Easy Read capabilities.

Plain English rewrites dense or technical text into clear, everyday language, while Easy Read presents information in short sentences and simple structure, in line with recognised accessibility standards. Together, they remove barriers to understanding for anyone who finds legal, financial or technical language difficult to navigate, including people with learning disabilities or limited literacy.

"We built askVERA because too many people are left confused or excluded by documents that should be straightforward," said Derek Kilroe, Chairman of askelie®. "Whether you're an individual trying to make sense of a letter from your landlord, or a business that wants its policies to actually be read and understood, askVERA gives you that clarity in seconds."

The B2C version lets individuals upload or paste any document and get an instant Plain English or Easy Read version, helping with everything from tenancy agreements to insurance policies. The B2B version integrates into an organisation's existing workflows, letting businesses simplify their customer-facing content at scale, supporting accessibility commitments and reducing queries caused by unclear communication.

askVERA has already been working with organisations including Cornwall Council to make important documents easier to understand ahead of today's wider launch.

askVERA is available now online via their website as a standalone subscription. For more information, visit askelie.io.

About askelie®

askelie® is a UK-based AI platform company who built ELIE - the Ever Learning Intelligent Engine. ELIE is the Operational AI Platform connecting people and systems. Its product suite includes intELIEdocs, askKIRA, Voice IntELIEgence and ELIEKonnect, alongside askVERA and AskTARA. askelie® is ISO 27001 certified and works with global organisations across regulated industries to remove friction from everyday operations.

SOURCE AskELIE Limited

Share this article